Physician profile
Leonard Perez
NPI 1053331710
$2,951.62
in general payments reported to CMS, 2019-2025
24 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $220 · 2021: $351 · 2022: $216 · 2023: $424 · 2024: $1,387 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158 · Travel and Lodging: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.76 |
| Travel and Lodging | $856.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,298.45 | 2023-2024 | Altis |
| Abbvie INC. | $527.68 | 2019-2023 | |
| Hologic Sales and Service, LLC | $168.97 | 2019-2024 | Thinprep 2000 Processor |
| Sumitomo Pharma America, INC. | $159.22 | 2023-2025 | Myfembree, Gemtesa |
| Sage Therapeutics, LLC | $107.04 | 2024-2025 | Zurzuvae |
| Agile Therapeutics, INC. | $95.45 | 2021-2023 | Twirla |
| Pfizer INC. | $76.99 | 2021-2022 | |
| Myovant Sciences INC. | $73.83 | 2021-2022 | |
| Shield Therapeutics INC | $62.69 | 2023-2025 | Accrufer |
| Organon LLC | $49.85 | 2021-2023 | Nexplanon |
| Daiichi Sankyo INC. | $45.40 | 2019-2023 | Injectafer |
| Allergan, INC. | $36.12 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $33.98 | 2020-2021 | |
| Coopersurgical, INC. | $33.49 | 2025 | Paragard T 380a |
| Astellas Pharma US INC | $33.10 | 2023-2024 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $26.61 | 2021 | |
| Medtronic USA, INC. | $22.02 | 2019 | |
| Therapeuticsmd, INC. | $21.02 | 2020 | |
| Smith+Nephew, INC. | $17.98 | 2023 | Grafix Pl |
| Meditrina | $17.56 | 2025 | |
| Roche Diagnostics Corporation | $14.80 | 2019 | |
| Lupin INC. | $12.59 | 2020 | |
| Axonics, INC. | $11.94 | 2022 | |
| Mayne Pharma Commercial LLC | $4.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.